{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:10:15Z","timestamp":1794258615995,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPF1P0071"],"award-info":[{"award-number":["CMRPF1P0071"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011813","name":"Changchun University of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011813","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2320-B-255-011"],"award-info":[{"award-number":["NSTC 112-2320-B-255-011"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bcp.2025.116876","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:14:30Z","timestamp":1742303670000},"page":"116876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["H1.0 modulates IL-6 expression and paclitaxel resistance via HDAC5 in ovarian cancer cells"],"prefix":"10.1016","volume":"236","author":[{"given":"Shang-Lang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting\u2010Chang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-3749","authenticated-orcid":false,"given":"Nian-Kang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116876_b0005","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2025.116876_b0010","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3802\/jgo.2018.29.e32","article-title":"Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism","volume":"29","author":"Li","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2025.116876_b0015","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2025.116876_b0020","doi-asserted-by":"crossref","first-page":"27065","DOI":"10.18632\/oncotarget.4824","article-title":"Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: analysis of the androgen receptor","volume":"6","author":"Sun","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.116876_b0025","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/cas.15448","article-title":"H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor","volume":"113","author":"Kohli","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2025.116876_b0030","doi-asserted-by":"crossref","first-page":"12622","DOI":"10.1016\/S0021-9258(17)38916-0","article-title":"Nonrandom location of H1-H1\u00b0 histones on chromatin of mouse liver and brain","volume":"260","author":"Delabar","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.116876_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568009033333754","article-title":"Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation","volume":"3","author":"Yusuf","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.bcp.2025.116876_b0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-018-0787-z","article-title":"Ccl2\/Ccl5 secreted by the stroma induce Il-6\/Pyk2 dependent chemoresistance in ovarian cancer","volume":"17","author":"Pasquier","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.116876_b0045","first-page":"3445","article-title":"Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype","volume":"5","author":"Duan","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116876_b0050","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bcp.2025.116876_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114456","article-title":"TLR4\/IL-6\/IRF1 signaling regulates androgen receptor expression: a potential therapeutic target to overcome taxol resistance in ovarian cancer","volume":"186","author":"Huang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116876_b0060","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0039-9140(97)00017-9","article-title":"A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability","volume":"44","author":"Ishiyama","year":"1997","journal-title":"Talanta"},{"key":"10.1016\/j.bcp.2025.116876_b0065","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/ijms22052622","article-title":"TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues","volume":"22","author":"Bartha","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116876_b0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.bcp.2025.116876_b0075","doi-asserted-by":"crossref","first-page":"10193","DOI":"10.1073\/pnas.90.21.10193","article-title":"Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8","volume":"90","author":"Matsusaka","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2025.116876_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100754","article-title":"Therapeutic strategies to overcome taxane resistance in cancer","volume":"55","author":"Das","year":"2021","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.bcp.2025.116876_b0085","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/jcp.26125","article-title":"TLR4 and NF\u03baB signaling is critical for taxol resistance in ovarian carcinoma cells","volume":"233","author":"Sun","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2025.116876_b0090","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ijc.28189","article-title":"Targeting the IL-4\/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs","volume":"133","author":"Natoli","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2025.116876_b0095","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fonc.2019.00421","article-title":"Macrophage polarization in the development and progression of ovarian cancers: an overview","volume":"9","author":"Cheng","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.116876_b0100","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.2147\/CMAR.S179189","article-title":"IL-6 and ovarian cancer: Inflammatory cytokines in promotion of metastasis","volume":"10","author":"Browning","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bcp.2025.116876_b0105","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2313671","article-title":"MUC1-EGFR crosstalk with IL-6 by activating NF-\u03baB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma","volume":"56","author":"Xu","year":"2024","journal-title":"Ann. Med."},{"key":"10.1016\/j.bcp.2025.116876_b0110","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","article-title":"Interleukin-6 as a therapeutic target in human ovarian cancer","volume":"17","author":"Coward","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116876_b0115","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1715064","article-title":"Prognostic and clinical value of interleukin 6 and CD45+CD14+ inflammatory cells with PD-L1+\/PD-L2+ expression in patients with different manifestations of ovarian cancer","volume":"2020","author":"Wertel","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bcp.2025.116876_b0120","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.3390\/jcm9092865","article-title":"Ascitic Interleukin 6 is associated with poor outcome and spontaneous bacterial peritonitis: a validation in critically Ill patients with decompensated cirrhosis","volume":"9","author":"Mayr","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2025.116876_b0125","doi-asserted-by":"crossref","first-page":"25900","DOI":"10.1074\/jbc.M707692200","article-title":"Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT\/IkappaB kinase alpha pathway targeting activator protein-1","volume":"283","author":"Cahill","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.116876_b0130","first-page":"2913","article-title":"Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis","volume":"62","author":"Huang","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.116876_b0135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s44161-024-00460-w","article-title":"Histone H1.0 couples cellular mechanical behaviors to chromatin structure","volume":"3","author":"Hu","year":"2024","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2025.116876_b0140","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.114.303429","article-title":"Regulation of acetylation of histone deacetylase 2 by p300\/CBP-associated factor\/histone deacetylase5 in the development of cardiac hypertrophy","volume":"114","author":"Eom","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2025.116876_b0145","doi-asserted-by":"crossref","first-page":"10782","DOI":"10.1038\/ncomms10782","article-title":"Hypothalamic leptin action ismediatedbyhistonedeacetylase5","volume":"7","author":"Kabra","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116876_b0150","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2025.116876_b0155","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","article-title":"Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours","volume":"46","author":"Mackay","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2025.116876_b0160","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/jcm13030897","article-title":"Carboplatin plus paclitaxel in combination with the histone deacetylate inhibitor, vorinostat, in patients with recurrent platinum-sensitive ovarian cancer","volume":"13","author":"Meteran","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2025.116876_b0165","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3390\/ijms20092135","article-title":"HDAC5 expression in urothelial carcinoma cell lines inhibits long-term proliferation but can promote epithelial-to-mesenchymal transition","volume":"20","author":"Jaguva Vasudevan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116876_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215971","article-title":"METTL3-mediated N6-methyladenosine modification and HDAC5\/YY1 promote IFFO1 downregulation in tumor development and chemo-resistance","volume":"553","author":"Zhang","year":"2023","journal-title":"Cancer Lett."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:25:05Z","timestamp":1762097105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225001388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"alternative-id":["S0006295225001388"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116876","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"H1.0 modulates IL-6 expression and paclitaxel resistance via HDAC5 in ovarian cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116876"}}